Kenneth Varian is a Cardiology physician affiliated with Summa Health System. OpenAlex indexes 35 publications with 485 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
95 Arch St Ste 300
Akron, OH 443041473
Telephone
330-253-8195Provider last certified this registry record 21 Apr 2020.
Clinical trials
- Assay to Measure Beta Blocker Adherence
Sponsor: Summa Health System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202524 payments$28,606openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year20254 payments
- BridgeBio Pharma, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
70.8%Aldosterone antagonist (MRA)16.7%Spironolactone91%Eplerenone9%Part D≥178 patientsBeta blocker14.2%Metoprolol Succinate65%Carvedilol32%Metoprolol Tartrate3%Part D<11 patients+ 13 more classes in this area
Metabolism & gastrointestinal
19.4%SGLT2 inhibitor13.1%Farxiga53%Jardiance47%Part D≥69 patientsGLP-1 receptor agonist5.5%Ozempic80%Mounjaro20%Part D<11 patients+ 1 more class in this area
Blood & clotting
9.8%Factor Xa inhibitor8.3%Eliquis85%Xarelto15%Part D≥78 patientsP2Y12 inhibitor1.5%Clopidogrel100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- UTILIZATION OF PERCUTANEOUS CORONARY INTERVENTION (PCI) IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) PATIENTS
Journal of the American College of Cardiology
2023 - THE PERFECT STORM OF COMPLICATIONS IN A RARE DISEASE
Journal of the American College of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Thomas File, MD
Summa Health System
Marc Penn, MD
Summa Health System
Drazen Petrinec, MD
Summa Health System
Sameer Mahesh, MD
Summa Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”